Format

Send to

Choose Destination
Hum Vaccin Immunother. 2017 Oct 3;13(10):2269-2271. doi: 10.1080/21645515.2017.1345833.

The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors.

Author information

1
a Blood Center of Wisconsin , Milwaukee , WI , USA.

Abstract

Recent advancements in adoptive cell therapy (ACT) are opening up new frontiers for cancer immunotherapy. CAR T cells targeting CD19 have emerged as a remarkable T cell-based therapy for the successful treatment of certain types of leukemia and lymphomas. Despite these clinical successes, as well as significant breakthroughs in T cell engineering, the treatment of solid tumors with ACT remains a relentless challenge. Thus, the current consensus of the field is that an urgent need exists for the design of innovative approaches that can improve the efficacy of ACT in treating solid cancers while maintaining a high degree of reliability and safety.

KEYWORDS:

engineered adoptive cell therapy; pathogen-boosted vaccination

PMID:
28708956
PMCID:
PMC5647994
DOI:
10.1080/21645515.2017.1345833
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center